Skip to main content

How Big Pharma rips you off on drugs

By Arthur Caplan and Zachary Caplan, Special to CNN
April 25, 2013 -- Updated 1312 GMT (2112 HKT)
Arthur and Zachary Caplan say brand-name Lipitor sold for $3.50 or more per pill.
Arthur and Zachary Caplan say brand-name Lipitor sold for $3.50 or more per pill.
STORY HIGHLIGHTS
  • The Supreme Court probably will decide in June on Federal Trade Commission v. Actavis
  • Arthur Caplan, Zachary Caplan: Big Pharma has kept prescription drug prices high
  • Caplans: The court's decision will affect our escalating national health care bill for drugs
  • They say the Supreme Court should end pay-for-delay and encourage market competition

Editor's note: Arthur Caplan is the Drs. William F and Virginia Connolly Mitty professor and director of the Division of Bioethics at New York University's Langone Medical Center. Zachary Caplan is his son and an attorney at a law firm in Philadelphia that filed an amicus brief on behalf of drug wholesalers and pharmacies in the case FTC v. Actavis.

(CNN) -- Whether you are young or old, man or woman, very healthy or quite sick, it is almost a certainty that you are going to use a prescription drug in the next year or two. These medicines are crucial for preventing diseases and treating all sorts of ailments and problems.

They are also expensive -- really expensive. For example, the best-selling drug of all time, Pfizer's cholesterol lowering drug Lipitor, went for $3.50 per pill and up before going generic in late 2011. But these days some retail chains are giving away generic Lipitor while the rest are charging barely 50 cents a pill.

Prescription drugs cost Americans far more than they do people living in many other parts of the world. This is because drug companies spend a fortune on direct-to-consumer sales and marketing (which they don't do in other countries) and because other nations negotiate better deals for drugs than private insurers do in the United States.

Arthur Caplan
Arthur Caplan

Is there anything that can be done to lower costs and increase the availability of more affordable and equally effective drugs? Yes.

Zachary Caplan
Zachary Caplan

Earlier this year, the U.S. Supreme Court heard arguments in a case that drew little attention in the media: Federal Trade Commission v. Actavis. The stakes are high.

When the court decides this case, probably in June, it will either reinforce Big Pharma shenanigans that have helped keep prices high and skyrocketing, or finally bring some relief to our pocketbook and escalating national health care bill for drugs.

The issue is whether companies that own patents for prescription drugs can pay other companies that want to make cheaper generic versions not to do so, a practice known as pay-for-delay.

One way to get lower prices on drugs is to get generic versions out to replace name-brand drugs. Generic drugs include the exact same active ingredients as the brand names. The difference is the name of the medication and the color or shape of the pill.

Become a fan of CNNOpinion
Stay up to date on the latest opinion, analysis and conversations through social media. Join us at Facebook/CNNOpinion and follow us @CNNOpinion on Twitter. We welcome your ideas and comments.



Prescription drug manufacturers, fearing the arrival of cheaper generics and knowing or worrying that their patents alone won't keep out competitors, try to buy off the competition instead.

In the case before the court, Solvay Pharmaceuticals is accused of paying off would-be generic manufacturers of their blockbuster drug AndroGel, a synthetic testosterone used by hundreds of thousands of AIDS patients, cancer patients, elderly men and others who suffer from low levels of testosterone. The generic companies were happy; they made money for doing nothing. Solvay continued to reap huge profits by keeping its monopoly in the market. The only losers were patients who have had to keep paying much higher prices for their name-brand-only drug.

Usually, buying off your competitors is clearly illegal. Pay-for-delay deals run counter to basic antitrust principles. Nonetheless, some lower courts, declining to evaluate the strength of a patent, have let Big Pharma get away with these deals.

Big Pharma views the settlements as a bargain. Instead of losing up to 90% of their market share bcause of the introduction of a generic, companies can simply pay generic manufacturers and make the competition go away.

A 1984 law, the Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch-Waxman Act, was intended to speed up lower-cost generic competition. Big Pharma has managed to completely undermine Hatch-Waxman's intent, which was to put in place mechanisms that encouraged generic drug makers to challenge the weak patents often used to protect brand-name drugs.

Unfortunately, the AndroGel case is not unique. In recent years, deals between Big Pharma and generic drug makers have delayed the introduction of a diverse range of cheaper generics including cancer drugs, AIDS treatments, blood pressure medications, antidepressants, allergy medications, sleep aids, ADD medications and more.

The Congressional Budget Office says pay-for-delay tactics cost consumers billions of dollars and the Federal Trade Commission estimates these pay-for-delay deals will cost Americans up to $35 billion over the next 10 years.

Rep. Henry Waxman, D-California, who co-wrote the Hatch-Waxman Act, has been very vocal in arguing that a law Congress intended to help reduce the cost of prescription medicines has been hijacked by the drug industry to do the opposite.

What we have now are the generic manufacturers and Big Pharma making a fortune by agreeing to delay competition that would bring lower priced drugs to market.

A few weeks ago, the Indian Supreme Court took a hard look at the way big drug companies were using patent extensions to keep out low price competition. They said forget it—that sort of tomfoolery will not be allowed.

The U.S. Supreme Court would be wise to concur, heed the Federal Trade Commission's complaint and bring pay-for-delay to an abrupt end.

The right prescription for making medicines cheaper and better is to encourage competition, not stifle it with backroom deals where everyone gets a great deal except for the patients.

Follow us on Twitter @CNNOpinion.

Join us on Facebook/CNNOpinion.

The opinions expressed in this commentary are solely those of Arthur Caplan and Zachary Caplan.

ADVERTISEMENT
Part of complete coverage on
September 13, 2014 -- Updated 1620 GMT (0020 HKT)
Joe Torre and Esta Soler say much has been achieved since a landmark anti-violence law was passed.
September 12, 2014 -- Updated 2055 GMT (0455 HKT)
David Wheeler wonders: If Scotland votes to secede, can America take its place and rejoin England?
September 12, 2014 -- Updated 2207 GMT (0607 HKT)
Jane Stoever: Society must grapple with a culture in which 1 in 3 teen girls and women suffer partner violence.
September 12, 2014 -- Updated 2036 GMT (0436 HKT)
World-famous physicist Stephen Hawking recently said the world as we know it could be obliterated instantaneously. Meg Urry says fear not.
September 12, 2014 -- Updated 2211 GMT (0611 HKT)
Bill Clinton's speech accepting the Democratic nomination for president in 1992 went through 22 drafts. But he always insisted on including a call to service.
September 12, 2014 -- Updated 2218 GMT (0618 HKT)
Joe Amon asks: What turns a few cases of disease into thousands?
September 12, 2014 -- Updated 1922 GMT (0322 HKT)
A Scottish vote for independence next week could trigger wave of separatist tension in Europe, says Frida Ghitis.
September 12, 2014 -- Updated 2212 GMT (0612 HKT)
You couldn't call him a "Bond villain" in the grand context of Dr. No or Auric Goldfinger. They were twisted visionaries of apocalypse whose ideas were to be played out at humanity's expense.
September 12, 2014 -- Updated 1705 GMT (0105 HKT)
As a Latina activist I was hurt to hear the President would delay executive action to keep undocumented immigrants with no criminal record from getting deported.
September 11, 2014 -- Updated 1721 GMT (0121 HKT)
Sally Kohn says bombing ISIS will worsen instability in Iraq and strengthen radical ideology in terrorist groups.
September 11, 2014 -- Updated 2224 GMT (0624 HKT)
Stevan Weine says the key is to stop young people from acquiring radicalized beliefs in the first place.
September 11, 2014 -- Updated 1730 GMT (0130 HKT)
Analysts weigh in on the president's plans for addressing the threat posed by the Islamic State of Iraq and Syria.
September 11, 2014 -- Updated 1227 GMT (2027 HKT)
US Currency is seen in this January 30, 2001 image. AFP PHOTO/Karen BLEIER (Photo credit should read KAREN BLEIER/AFP/Getty Images)
Lisa Gilbert says a million people have asked the SEC to make corporations disclose political contributions.
September 11, 2014 -- Updated 0455 GMT (1255 HKT)
Christi Paul says unless you've walked in an abused woman's shoes, don't judge her, help her get answers to the right questions: Why does he get to hit her? And why does nobody do anything to stop him?
September 10, 2014 -- Updated 1932 GMT (0332 HKT)
Mel Robbins says several other NFL players arrested recently in domestic violence are back on the field. Roger Goodell has shown he is clueless on abuse. He must go.
September 10, 2014 -- Updated 1759 GMT (0159 HKT)
Newt Gingrich says President Obama has a remarkable opportunity Wednesday night to mobilize support for a coalition against ISIS.
September 11, 2014 -- Updated 0041 GMT (0841 HKT)
The Texas senator says Obama should seek congressional authorization for a major bombing campaign vs. ISIS.
September 11, 2014 -- Updated 1327 GMT (2127 HKT)
Artist Prune Nourry's project reinterprets the terracotta warriors in an exhibition about gender preference in China.
September 10, 2014 -- Updated 1336 GMT (2136 HKT)
The Apple Watch is on its way. Jeff Yang asks: Are we ready to embrace wearables technology at last?
ADVERTISEMENT